Calgary, Alberta ‐ August 19, 2026 ‐ Marvel Biosciences Corp. (TSXV: MRVL OTCQB: MBCOF) (“Marvel” or the “Company”) announces that it is expanding its previously announced private placement (see July 16, 2026 press release) to investors...
Calgary, Alberta – August 5, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum...
Calgary, Alberta ‐ July 16, 2026 ‐ Marvel Biosciences Corp. (TSXV: MRVL OTCQB: MBCOF) (“Marvel” or the “Company”) is pleased to announce that it intends to complete a non‐brokered private placement offering (the “Offering”) of units of the...
Calgary, Alberta – June 26, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel therapeutics for autism spectrum...
Calgary, Alberta – June 8, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel, therapeutics for autism spectrum...
Calgary, Alberta, Canada, May 20, 2026 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announces the award of 50,001 deferred share units (“DSUs”) to Marvel’s three...
